

Nicolai J Birkbak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7953682/publications.pdf>

Version: 2024-02-01

23
papers

10,618
citations

430442
18
h-index

676716
22
g-index

25
all docs

25
docs citations

25
times ranked

17704
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract 6091: Evolutionary characterisation of lung adenocarcinoma pathological subtypes in TRACERx. Cancer Research, 2022, 82, 6091-6091.	0.4	0
2	Treatment Represents a Key Driver of Metastatic Cancer Evolution. Cancer Research, 2022, 82, 2918-2927.	0.4	11
3	Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer. Cancer Research Communications, 2022, 2, 762-771.	0.7	6
4	Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma. Cancers, 2022, 14, 3342.	1.7	9
5	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301.	5.8	159
6	Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 2021, 597, 555-560.	13.7	36
7	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	13.7	221
8	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	2.9	51
9	Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nature Genetics, 2020, 52, 283-293.	9.4	168
10	Cancer Genome Evolutionary Trajectories in Metastasis. Cancer Cell, 2020, 37, 8-19.	7.7	140
11	E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells. Journal of Cell Biology, 2020, 219, .	2.3	13
12	Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nature Medicine, 2019, 25, 1549-1559.	15.2	147
13	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	15.2	75
14	Neoantigen-directed immune escape in lung cancer evolution. Nature, 2019, 567, 479-485.	13.7	639
15	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	13.5	472
16	Chromosomal instability drives metastasis through a cytosolic DNA response. Nature, 2018, 553, 467-472.	13.7	1,002
17	Early stage NSCLC â€” challenges to implementing ctDNA-based screening and MRD detection. Nature Reviews Clinical Oncology, 2018, 15, 577-586.	12.5	281
18	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	13.7	1,287

#	ARTICLE	IF	CITATIONS
19	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	13.9	1,786
20	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	13.5	968
21	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	9.4	423
22	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
23	Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics, 2011, 12, 474.	1.2	277